Novalis Biotechnology Incubation
Novalis Biotech is an early-stage venture capital fund focused on enabling technologies in life sciences. The firm invests in capital-light platform technologies from (pre-)seed to Series A, concentrating on bioinformatics, genomics, diagnostics, digital health, research and manufacturing tools. Novalis provides funding and active operational support including strategic guidance, network access and governance representation to accelerate commercialization and company development.
Novalis Biotechnology Incubation
Gent, Oost-Vlaanderen, Belgium, Europe
Services
Equity funding (early-stage)
Provides seed to Series A equity investments through Novalis Biotech funds, including participation in follow-on rounds and fund-led seed extensions.
Strategic guidance and business development support
Advises portfolio companies on business strategy and market positioning and supports commercialization and scale-up activities.
Network access and academic connections
Provides introductions to professional and academic contacts to help validate technology, find early customers and enable collaborations.
Board representation and governance support
Seeks representation on portfolio companies' governance bodies and provides ongoing monitoring of compliance and governance matters.
Due diligence and regulatory monitoring
Conducts pre-investment due diligence including assessment of compliance with applicable legislation (including ESG-related legislation) and monitors portfolio companies over the investment lifespan.
Portfolio
List of portfolio companies and notable portfolio activities.
Equity funding (early-stage)
Provides seed to Series A equity investments through Novalis Biotech funds, including participation in follow-on rounds and fund-led seed extensions.
Strategic guidance and business development support
Advises portfolio companies on business strategy and market positioning and supports commercialization and scale-up activities.
Network access and academic connections
Provides introductions to professional and academic contacts to help validate technology, find early customers and enable collaborations.
Board representation and governance support
Seeks representation on portfolio companies' governance bodies and provides ongoing monitoring of compliance and governance matters.
Due diligence and regulatory monitoring
Conducts pre-investment due diligence including assessment of compliance with applicable legislation (including ESG-related legislation) and monitors portfolio companies over the investment lifespan.
Portfolio
List of portfolio companies and notable portfolio activities.
Portfolio
ISO 13485:2016 and ISO 27001:2013-certified; CE-marked and FDA-cleared electrophysiology applications; Novalis listed as investor in 2025 news item.
#MedTech (electrophysiology, CNS applications)
AI analysis of standard medical images to detect early joint damage; Novalis participated in seed investment.
#Medical imaging AI (rheumatology)
Developing 'Artificial Voice' using non-invasive radar sensing and neural networks; Novalis participated in Series A.
#Medical device (AI-based voice rehabilitation)
Develops superRCA ultrasensitive multiplex assay read out by flow cytometry; Novalis invested and participated in funding rounds (2023, 2024).
#Genomics / molecular diagnostics
Digital health solution for diagnosis and management of cough-related conditions; Novalis participated in seed extension.
#Digital health (cough assessment and monitoring)
Patented microcarrier technology enabling 3D cell cultivation; partnership with Etablissement Français du Sang (EFS) validated microcarriers and led to early commercial orders.
#Biomanufacturing / cell culture microcarriers
ISO 13485:2016 and ISO 27001:2013-certified; CE-marked and FDA-cleared electrophysiology applications; Novalis listed as investor in 2025 news item.
#MedTech (electrophysiology, CNS applications)
AI analysis of standard medical images to detect early joint damage; Novalis participated in seed investment.
#Medical imaging AI (rheumatology)
Developing 'Artificial Voice' using non-invasive radar sensing and neural networks; Novalis participated in Series A.
#Medical device (AI-based voice rehabilitation)
Develops superRCA ultrasensitive multiplex assay read out by flow cytometry; Novalis invested and participated in funding rounds (2023, 2024).
#Genomics / molecular diagnostics
Digital health solution for diagnosis and management of cough-related conditions; Novalis participated in seed extension.
#Digital health (cough assessment and monitoring)
Patented microcarrier technology enabling 3D cell cultivation; partnership with Etablissement Français du Sang (EFS) validated microcarriers and led to early commercial orders.
#Biomanufacturing / cell culture microcarriers